JAK2 and myeloproliferative neoplasm: In contrast, JAK2V617F [42], a constitutive active mutant of Janus kinase 2 (JAK2) that is found in patients with myeloproliferative neoplasms, phosphorylates PRMT5 and downregulates its activity [43].